Treatment of exudative age‐related macular degeneration with aflibercept combined with pranoprofen eye drops or nutraceutical support with omega‐3: A randomized trial

@article{Semeraro2019TreatmentOE,
  title={Treatment of exudative age‐related macular degeneration with aflibercept combined with pranoprofen eye drops or nutraceutical support with omega‐3: A randomized trial},
  author={F. Semeraro and Elena Gambicordi and A. Cancarini and F. Morescalchi and C. Costagliola and A. Russo},
  journal={British Journal of Clinical Pharmacology},
  year={2019},
  volume={85},
  pages={908 - 913}
}
  • F. Semeraro, Elena Gambicordi, +3 authors A. Russo
  • Published 2019
  • Medicine
  • British Journal of Clinical Pharmacology
    • The aim of this study was to determine whether a combination of intravitreal aflibercept (IVA) and pranoprofen eyedrops or nutraceutical support provides additional benefit over IVA monotherapy for the treatment of choroidal neovascularization (CNV) in age‐related macular degeneration. 
    View on Wiley
    bpspubs.onlinelibrary.wiley.com
    2 Citations
    2 Citations
    Citation Type

    Citation Type

    Clinical outcomes of 1 + PRN and 3 + Q3M regimens of intravitreal conbercept injection for exudative age-related macular degeneration
    • 1
    • PDF
    Nutritional Supplements in the Prevention of Age-Related Retinal Pathology

    References

    SHOWING 1-10 OF 36 REFERENCES
    Ranibizumab in neovascular age-related macular degeneration
    • 1,735
    • Highly Influential
    Topical Nonsteroidal Anti-Inflammatory Drugs for Macular Edema
    • 38
    • PDF
    Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
    • 1,398
    • PDF
    TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH RANIBIZUMAB COMBINED WITH KETOROLAC EYEDROPS OR PHOTODYNAMIC THERAPY
    • 16
    Omega-3 Supplementation Combined With Anti–Vascular Endothelial Growth Factor Lowers Vitreal Levels of Vascular Endothelial Growth Factor in Wet Age-Related Macular Degeneration
    • 22
    PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF COMBINATION RANIBIZUMAB (LUCENTIS) AND BROMFENAC (XIBROM) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Pilot Study
    • 36
    A randomised controlled trial of ranibizumab with and without ketorolac eyedrops for exudative age-related macular degeneration
    • 14
    TOPICAL BROMFENAC AS AN ADJUNCTIVE TREATMENT WITH INTRAVITREAL RANIBIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
    • 38
    Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3.
    • 225
    • PDF
    The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1).
    • 170
    • PDF